Abbvie Inc (ABBV)

$248.76 -1.33 (-0.53%)
Market Cap 441.86B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 22.81
Forward PE 17.63
Profit Margin 6.91%
Debt to Equity Ratio -12.03
Volume 3,780,400
Avg Vol 7,071,196
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 50%
Beta 0.30
Analysts Strong Sell
Price Target $274.59

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
CapitalMonk
CapitalMonk Aug. 13 at 2:55 AM
$ABBV Price: $248.76 (-0.53%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±1.18% RSI: 40.5 | Momentum: Moderate Volume: -47.3% vs avg Volatility: 1.64% Support: $241.20 | Resistance: $267.47 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 13 at 1:52 AM
$ABBV $500 per share soon?
0 · Reply
GordoHLYK13
GordoHLYK13 Aug. 13 at 12:50 AM
$IGC get ready to da moon https://youtu.be/VTi76gvDGIc?is=wBk4qhvfjxoZ9sAe $ABBV $MRNA $PFE
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 13 at 12:31 AM
$SLS PSA for the New(er) Investors: Aza+VEN the Best Available Treatment (BAT) for the SLS P3 CONTROL Arm CR2 patients - Recently Failed 3 Large Phase 3 Trials conducted by $ABBV • VERONA - high risk MDS/AML Precursor Phase 3 FAILED • VIALE-T - Post Transplant AML Maintenance Trial FAILED • VIALE-M - First Remission CR1 Maintenance Trial FAILED M trial failed 7 different attempted Dosing Regimes, reduced intensity, all Oral -- it is too toxic for Maintenance. • VIALE-A patietnts had - 83% Serious Adverse Reaction • 23% of the Viale A patients taking Aza VEN DIED from taking AzaVEN BAT is NOT Why we are seeing miraculous extended survival - it is GPs, doing what its done in all 7 prior trials, prevent relapse and extend survival including in 4 Phase 2 Trials - 2 for AML Remission ...
0 · Reply
TechridyStocks
TechridyStocks Aug. 12 at 10:22 PM
$ABBV 👀👀🆙
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 12 at 9:02 PM
Here we go again? #trending #yet? ​$OTLK $ABBV $REGN $JNJ
0 · Reply
GordoHLYK13
GordoHLYK13 Aug. 12 at 10:14 AM
$ABBV $BMY $IGC $LLY IGC Pharma is strengthening its clinical, AI, and regulatory capabilities as it prepares for the completion of the Phase 2 CALMA trial. The goal is to support clinical data review, AI-driven data quality, potential FDA and EMA regulatory discussions, and strategic interest from potential pharmaceutical partners. As part of this preparation, IGC has brought on OPIS Research, a global contract research organization founded in Italy, to help support potential EMA regulatory interactions—putting the company in position to move quickly if the CALMA results are positive. 🚀📈
1 · Reply
GordoHLYK13
GordoHLYK13 Aug. 12 at 10:08 AM
$IGC This is why this is GOOD NEWS for IGC: 🚀🔥 Enrollment is essentially complete with 160 patients randomized, well above the original 146-patient target. That reduces the risk of enrollment delays and keeps the Phase 2 CALMA trial on track for its Q4 2026 topline readout. The additional patients also provide a cushion against attrition and could strengthen the overall dataset. At the same time, IGC is building out its research, regulatory, and AI/data infrastructure, putting the company in a better position to move quickly if the results are positive. Bottom line: The trial is wrapping up, the Q4 data catalyst is getting closer, and IGC is preparing for the next phase. It’s not the answer to the exam yet—but the test is nearly finished, and now we wait for the results. 👀📊🔥 $LLY $BMY $ABBV
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 11 at 7:19 PM
$1.00 on $ABBV here! 📉17% return! 🚀
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 11 at 7:10 PM
ADDING HEAVY!!🚀🚀 $ABBV 14 AUG 26 $255 CALL $0.85 DOUBLE INSIDE BAR + GAP ABOVE + PRICE UPGRADE + SECTOR STRENGTH
0 · Reply
Latest News on ABBV
AbbVie price target raised to $260 from $246 at Evercore ISI

2026-08-10T12:16:02.000Z - 2 days ago

AbbVie price target raised to $260 from $246 at Evercore ISI

AbbVie upgraded to Buy from Hold at Erste Group

2026-08-05T14:36:14.000Z - 7 days ago

AbbVie upgraded to Buy from Hold at Erste Group

AbbVie’s Botox Cosmetic sBLA for masseter muscle prominence accepted by FDA

2026-08-04T13:35:25.000Z - 8 days ago

AbbVie’s Botox Cosmetic sBLA for masseter muscle prominence accepted by FDA

AbbVie’s Allergan Aesthetics receives FDA approval of sBLA for Botox Cosmetic

2026-08-04T12:10:59.000Z - 8 days ago

AbbVie’s Allergan Aesthetics receives FDA approval of sBLA for Botox Cosmetic

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

Aug 4, 2026, 8:00 AM EDT - 8 days ago

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

AbbVie price target raised to $288 from $261 at Guggenheim

2026-08-04T10:52:04.000Z - 8 days ago

AbbVie price target raised to $288 from $261 at Guggenheim

AbbVie price target raised to $285 from $265 at Cantor Fitzgerald

2026-08-03T12:42:03.000Z - 9 days ago

AbbVie price target raised to $285 from $265 at Cantor Fitzgerald

AbbVie price target raised to $296 from $278 at Morgan Stanley

2026-08-03T12:06:31.000Z - 9 days ago

AbbVie price target raised to $296 from $278 at Morgan Stanley

AbbVie price target raised to $290 from $282 at Canaccord

2026-08-03T11:06:04.000Z - 9 days ago

AbbVie price target raised to $290 from $282 at Canaccord

AbbVie says ‘quite pleased’ with Skyrizi momentum

2026-07-31T14:01:14.000Z - 12 days ago

AbbVie says ‘quite pleased’ with Skyrizi momentum

AbbVie raises FY26 revenue view to about $67.6B from about $67.3B

2026-07-31T13:31:24.000Z - 12 days ago

AbbVie raises FY26 revenue view to about $67.6B from about $67.3B

AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84

2026-07-31T13:30:48.000Z - 12 days ago

AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

2026-07-31T13:30:35.000Z - 12 days ago

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

AbbVie says continues to make ‘excellent progress’ advancing pipeline

2026-07-31T13:16:13.000Z - 12 days ago

AbbVie says continues to make ‘excellent progress’ advancing pipeline

AbbVie Earnings Call Transcript: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 12 days ago

AbbVie Earnings Call Transcript: Q2 2026

AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 12 days ago

AbbVie Earnings release: Q2 2026

AbbVie Quarterly report: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 12 days ago

AbbVie Quarterly report: Q2 2026

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

Jul 31, 2026, 8:36 AM EDT - 12 days ago

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.

Jul 31, 2026, 8:31 AM EDT - 12 days ago

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.

AbbVie reports Q2 adjusted EPS $3.65, consensus $3.61

2026-07-31T11:51:57.000Z - 12 days ago

AbbVie reports Q2 adjusted EPS $3.65, consensus $3.61

AbbVie cuts FY26 adjusted EPS view to $13.87-$14.07 from $13.91-$14.11

2026-07-31T11:50:17.000Z - 12 days ago

AbbVie cuts FY26 adjusted EPS view to $13.87-$14.07 from $13.91-$14.11

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

Jul 31, 2026, 7:50 AM EDT - 12 days ago

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

AbbVie Reports Second-Quarter 2026 Financial Results

Jul 31, 2026, 7:47 AM EDT - 12 days ago

AbbVie Reports Second-Quarter 2026 Financial Results

JUVÉDERM® Day Returns to U.S. on August 19

Jul 30, 2026, 8:00 AM EDT - 13 days ago

JUVÉDERM® Day Returns to U.S. on August 19

AbbVie announces Elahere availability in Singapore

2026-07-29T09:30:43.000Z - 15 days ago

AbbVie announces Elahere availability in Singapore

AbbVie announces European Commission approval for Rinvoq

2026-07-29T09:15:30.000Z - 15 days ago

AbbVie announces European Commission approval for Rinvoq

AbbVie price target raised to $300 from $275 at Barclays

2026-07-29T09:10:59.000Z - 15 days ago

AbbVie price target raised to $300 from $275 at Barclays

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jul 29, 2026, 3:00 AM EDT - 15 days ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

Jul 29, 2026, 3:00 AM EDT - 15 days ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jul 23, 2026, 4:00 PM EDT - 20 days ago

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

GMAB

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jul 17, 2026, 8:00 AM EDT - 26 days ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Jul 14, 2026, 8:05 AM EDT - 4 weeks ago

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Jul 13, 2026, 5:06 PM EDT - 4 weeks ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

APGE SBIO

Buy these quality, low-stress stocks for the summer, says Jefferies

Jul 7, 2026, 11:45 AM EDT - 5 weeks ago

Buy these quality, low-stress stocks for the summer, says Jefferies

AXP HD LOW MCD NFLX PEP PG

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Jul 6, 2026, 1:45 PM EDT - 5 weeks ago

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

US House committee opens investigation into Merck, AbbVie China drug trials

Jun 30, 2026, 6:02 AM EDT - 6 weeks ago

US House committee opens investigation into Merck, AbbVie China drug trials

MRK

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jun 29, 2026, 4:15 PM EDT - 6 weeks ago

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:10 AM EDT - 6 weeks ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

Jun 29, 2026, 3:00 AM EDT - 6 weeks ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 4:50 PM EDT - 6 weeks ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 6 weeks ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 6 weeks ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 7 weeks ago

AbbVie's $11 Billion Immunology Bet

APGE

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Jun 24, 2026, 8:00 AM EDT - 7 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jun 23, 2026, 8:00 AM EDT - 7 weeks ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 5:00 AM EDT - 7 weeks ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Jun 23, 2026, 3:00 AM EDT - 7 weeks ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

EC

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

Jun 22, 2026, 10:30 AM EDT - 7 weeks ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 7 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 7 weeks ago

AbbVie Transcript: M&A announcement

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 7 weeks ago

AbbVie Slides: M&A announcement

AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 7 weeks ago

AbbVie Press release: M&A announcement

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 7 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

Jun 22, 2026, 7:06 AM EDT - 7 weeks ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 7 weeks ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

Jun 22, 2026, 7:00 AM EDT - 7 weeks ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

AbbVie would gain an experimental eczema drug by buying biotech: report

Jun 20, 2026, 12:11 PM EDT - 7 weeks ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

Jun 19, 2026, 11:17 AM EDT - 7 weeks ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 7 weeks ago

AbbVie Declares Quarterly Dividend

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 16, 2026, 8:00 AM EDT - 2 months ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 12, 2026, 3:00 AM EDT - 2 months ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 10, 2026, 11:47 AM EDT - 2 months ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:40 AM EDT - 2 months ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 8, 2026, 8:00 AM EDT - 2 months ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 7:04 PM EDT - 2 months ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Jun 3, 2026, 3:30 AM EDT - 2 months ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 29, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 6:18 PM EDT - 2 months ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 2 months ago

US FDA approves AbbVie's rare blood cancer drug

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 22, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 6:46 PM EDT - 2 months ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 21, 2026, 4:10 PM EDT - 2 months ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

CapitalMonk
CapitalMonk Aug. 13 at 2:55 AM
$ABBV Price: $248.76 (-0.53%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±1.18% RSI: 40.5 | Momentum: Moderate Volume: -47.3% vs avg Volatility: 1.64% Support: $241.20 | Resistance: $267.47 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 13 at 1:52 AM
$ABBV $500 per share soon?
0 · Reply
GordoHLYK13
GordoHLYK13 Aug. 13 at 12:50 AM
$IGC get ready to da moon https://youtu.be/VTi76gvDGIc?is=wBk4qhvfjxoZ9sAe $ABBV $MRNA $PFE
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 13 at 12:31 AM
$SLS PSA for the New(er) Investors: Aza+VEN the Best Available Treatment (BAT) for the SLS P3 CONTROL Arm CR2 patients - Recently Failed 3 Large Phase 3 Trials conducted by $ABBV • VERONA - high risk MDS/AML Precursor Phase 3 FAILED • VIALE-T - Post Transplant AML Maintenance Trial FAILED • VIALE-M - First Remission CR1 Maintenance Trial FAILED M trial failed 7 different attempted Dosing Regimes, reduced intensity, all Oral -- it is too toxic for Maintenance. • VIALE-A patietnts had - 83% Serious Adverse Reaction • 23% of the Viale A patients taking Aza VEN DIED from taking AzaVEN BAT is NOT Why we are seeing miraculous extended survival - it is GPs, doing what its done in all 7 prior trials, prevent relapse and extend survival including in 4 Phase 2 Trials - 2 for AML Remission ...
0 · Reply
TechridyStocks
TechridyStocks Aug. 12 at 10:22 PM
$ABBV 👀👀🆙
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 12 at 9:02 PM
Here we go again? #trending #yet? ​$OTLK $ABBV $REGN $JNJ
0 · Reply
GordoHLYK13
GordoHLYK13 Aug. 12 at 10:14 AM
$ABBV $BMY $IGC $LLY IGC Pharma is strengthening its clinical, AI, and regulatory capabilities as it prepares for the completion of the Phase 2 CALMA trial. The goal is to support clinical data review, AI-driven data quality, potential FDA and EMA regulatory discussions, and strategic interest from potential pharmaceutical partners. As part of this preparation, IGC has brought on OPIS Research, a global contract research organization founded in Italy, to help support potential EMA regulatory interactions—putting the company in position to move quickly if the CALMA results are positive. 🚀📈
1 · Reply
GordoHLYK13
GordoHLYK13 Aug. 12 at 10:08 AM
$IGC This is why this is GOOD NEWS for IGC: 🚀🔥 Enrollment is essentially complete with 160 patients randomized, well above the original 146-patient target. That reduces the risk of enrollment delays and keeps the Phase 2 CALMA trial on track for its Q4 2026 topline readout. The additional patients also provide a cushion against attrition and could strengthen the overall dataset. At the same time, IGC is building out its research, regulatory, and AI/data infrastructure, putting the company in a better position to move quickly if the results are positive. Bottom line: The trial is wrapping up, the Q4 data catalyst is getting closer, and IGC is preparing for the next phase. It’s not the answer to the exam yet—but the test is nearly finished, and now we wait for the results. 👀📊🔥 $LLY $BMY $ABBV
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 11 at 7:19 PM
$1.00 on $ABBV here! 📉17% return! 🚀
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 11 at 7:10 PM
ADDING HEAVY!!🚀🚀 $ABBV 14 AUG 26 $255 CALL $0.85 DOUBLE INSIDE BAR + GAP ABOVE + PRICE UPGRADE + SECTOR STRENGTH
0 · Reply
Mantraset3
Mantraset3 Aug. 11 at 7:07 PM
$ABBV why bearish? I ❤️ this stock she has been good to me
0 · Reply
Equityforge01
Equityforge01 Aug. 11 at 7:03 PM
$1.00 on $ABBV here! 17% return$ABBV
0 · Reply
Blockwave01
Blockwave01 Aug. 11 at 7:03 PM
$1.00 on $ABBV here! 17% return!
0 · Reply
Alphatrades09
Alphatrades09 Aug. 11 at 7:02 PM
$1.00 on $ABBV here! 🩺 17% return! 🔥
0 · Reply
Blockwave01
Blockwave01 Aug. 11 at 7:00 PM
$ABBV 14 AUG 26 $255 CALL $0.85 DOUBLE INSIDE BAR + GAP ABOVE + PRICE UPGRADE + SECTOR SENTIMENT
0 · Reply
LUXtrades0
LUXtrades0 Aug. 11 at 6:59 PM
$ABBV 14 AUG 26 $255 CALL $0.85 🤾🏼‍♂️
0 · Reply
Alphatrades09
Alphatrades09 Aug. 11 at 6:58 PM
$ABBV 255C 8/14 @ 0.85 🔥
0 · Reply
Equityforge01
Equityforge01 Aug. 11 at 6:58 PM
$ABBV 14 AUG 26 $255 CALL $0.85
0 · Reply
HydrogenH2
HydrogenH2 Aug. 11 at 4:37 PM
$ABBV AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry? Yep!! a little more !!
0 · Reply
NRG8
NRG8 Aug. 11 at 3:07 PM
$AVGO $V $MA $JNJ $ABBV
0 · Reply
Mergerbrief
Mergerbrief Aug. 11 at 12:12 PM
$APGE / $ABBV – Shareholder Vote APGE
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 10 at 11:39 PM
$SLS Gps achieved a MOS of > 67.6 Months, Not Reached - in a Phase 2, First Remission (CR1) Trial for Transplant Ineligible Patients. Same Exact setting as: -- MDACC Published Data this month: 17.3 Months MOS in • Combined Onureg / Oral Aza with VEN - MOS of 17.3 Months - which is less than -• ORAL AZA/Onureg MOS of 24.7 Months / BAT in CR1 absent transplant -•-GPS MOS > 67.6 Months in CR1 vs 24.7 months w BAT in CR1 - it is not complicated. $ABVX $XBI $ABBV https://www.reddit.com/r/sellasLifescience/comments/1rkz01h/a_look_back_at_the_rd_day_last_october/?share_id=XOuNI3RLlMsoh8jHKK-LI&utm_content=share_button&utm_medium=web3x&utm_name=web3xcss&utm_source=share&utm_term=1
1 · Reply